Valoración y tratamiento nutricional de la sarcopenia

Malafarina, Vincenzo; Úriz-Otano, Francisco; Gil-Guerrero, Lucía

doi:10.1016/j.regg.2013.03.005

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lo anterior, conlleva a la pérdida progresiva de peso a partir de los 65 años (250-500 g/año), acompañado de una disminución de la masa muscular de unos 3 kg/década, lo cual podría originar Sp 33 . Por lo tanto, la práctica de estilos de vida saludable se convierte en una medida preventiva en el desarrollo de la Sp 32 .…”

Section: Fisiopatologíaunclassified

“…Mediante audiencias sanitarias, clases destinadas a los adultos mayores o consejos en consulta, se podría establecer la base de una intervención nutricional y de actividad física controlada para lograr la corrección del sedentarismo y conductas alimentarias inadecuadas, lo cual mejoraría la salud y favorecería un envejecimiento saludable y activo 27,32 .…”

Section: Fisiopatologíaunclassified

See 1 more Smart Citation

Generalidades y tratamiento de la Sarcopenia

Hernández‐Rodríguez

Licea-puig

2017

revmed

View full text Add to dashboard Cite

RESUMENIntroducción: la sarcopenia hace referencia a la disminución de la masa y fuerza muscular relacionada con los mecanismos del envejecimiento y genera un compromiso funcional de alto costo, por lo tanto la presente revisión describe su tratamiento actual. Metodología de búsqueda: se realizó una búsqueda bibliográfica en las bases de datos Pubmed, Cochrane, LILACS, SciELO y el motor de búsqueda Google Scholar, seleccionándose 140 artículos para revisión de los cuales 48 artículos originales y 50 revisiones fueron referenciados. Discusión: como tratamiento en las personas de edad, se recomienda la ingesta de al menos 1,2 g/kg de proteína al día, acompañada de un aporte suficiente de micronutrientes y ocasionalmente de suplementos proteicos. Los programas de entrenamiento de fuerza en personas mayores es actualmente un método útil para la misma. El uso de fármacos debe ser evaluado individualmente. Generalities and treatment of Sarcopenia AbStRACtIntroduction: the sarcopenia makes reference to the mass and muscular force's decrease related with the mechanisms of the aging and generates a functional commitment of high cost, therefore the present revision describes its current treatment. Methodology: a bibliographic search was carried out in Pubmed, Cochrane, LILACS, SciELO and Google Scholar databases, selecting 140 articles to be reviewed of which 48 original articles and 50 reviews were referenced. Discussion: as a treatment for sarcopenia in elderly population, it is recommended to take at least 1.2 g/kg of protein per day, accompanied by a sufficient supply of micronutrients and occasional protein supplements. Strength training programs in older people is currently a useful method to combat this condition. The use of drugs should be evaluated individually. Conclusions: to prevent and treat sarcopenia, adequate nutrition and resistance exercise are the main pillars of treatment. MÉD.UIS. 2017;30(2):71-81.

show abstract

Section: Fisiopatologíaunclassified

Generalidades y tratamiento de la Sarcopenia

Hernández‐Rodríguez

Licea-puig

2017

revmed

View full text Add to dashboard Cite

show abstract

“…Population aging is a worldwide phenomenon which has been expressive and accelerated over the years [1]. Therefore, geriatric syndromes, such as sarcopenia with a higher prevalence among institutionalised older adults (14-33%) than those living in community (1-29%) [2,3], has a considerable clinical and research interest [4]. The most widely used definition of sarcopenia is the one of the European Working Group on Sarcopenia in Older People (EWGSOP) [5,6], which was updated in 2018 (EWGSOP2) and focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the diagnosis and identifies poor physical performance as indicative of severity [7].…”

Section: Introductionmentioning

confidence: 99%

Functional and Clinical Characteristics for Predicting Sarcopenia in Institutionalised Older Adults: Identifying Tools for Clinical Screening

Iranzo

Arnal‐Gómez

Chuliá

et al. 2020

IJERPH

View full text Add to dashboard Cite

Background: Recently, the European Working Group on Sarcopenia in Older People (EWGSOP2) has updated the sarcopenia definition based on objective evaluation of muscle strength, mass and physical performance. The aim of this study was to analyse the relationship between sarcopenia and clinical aspects such as functionality, comorbidity, polypharmacy, hospitalisations and falls in order to support sarcopenia screening in institutionalised older adults, as well as to estimate the prevalence of sarcopenia in this population using the EWGSOP2 new algorithm. Methods: A multicentre cross-sectional study was conducted on institutionalised older adults (n = 132, 77.7% female, mean age 82 years). Application of the EWGSOP2 algorithm consisted of the SARC-F questionnaire, handgrip strength (HG), appendicular skeletal muscle mass index (ASMI) and Short Physical Performance Battery (SPPB). Clinical study variables were: Barthel Index (BI), Abbreviated Charlson’s Comorbidity Index (ACCI), number of medications, hospital stays and falls. Results: Age, BI and ACCI were shown to be predictors of the EWGSOP2 sarcopenia definition (Nagelkerke’s R-square = 0.34), highlighting the ACCI. Sarcopenia was more prevalent in older adults aged over 85 (p = 0.005), but no differences were found according to gender (p = 0.512). Conclusion: BI and the ACCI can be considered predictors that guide healthcare professionals in early sarcopenia identification and therapeutic approach.

show abstract